Shanghai Hengrui Pharmaceutical Co., Ltd.
31 active trials across 7 therapeutic areas
31
Active Trials
21
Phase 1
21
Phase 2
2
Phase 3
7
Therapeutic Areas
Portfolio Concentration: 74% of active trials in Oncology
Oncology
23 active / 25 total
Solid Tumor (Advanced)
13 active
15 total since 2015
NSCLC
3 active
3 total since 2015
Bladder Cancer
3 active
1 Ph3
3 total since 2015
Pancreatic Cancer
1 active
1 total since 2015
Esophageal Cancer
1 active
1 total since 2015
Hodgkin Lymphoma
1 active
1 total since 2015
Multiple Myeloma
1 active
1 total since 2015
Immunology
3 active / 8 total
Pain
1 active / 4 total
CNS
1 active / 3 total
Respiratory
1 active / 3 total
Urology
1 active / 3 total
Cardiovascular
1 active / 2 total
Click an indication to see competitive landscape (all sponsors in that indication).
Data: ClinicalTrials.gov (2015+)